公开(公告)号：US20250042843A1

公开(公告)日：2025-02-06

申请号：US18597537

申请日：2024-03-06

Applicant: Tetraphase Pharmaceuticals, Inc.

Inventor： Jingye Zhou ,  Xiao-Yi Xiao ,  Louis Plamondon ,  Diana K. Hunt ,  Roger B. Clark ,  Robert Zahler

IPC: C07C233/57 ,  A61K31/65 ,  A61K45/06 ,  C07C311/08 ,  C07C311/21 ,  C07D205/04 ,  C07D207/06 ,  C07D207/08 ,  C07D207/09 ,  C07D207/10 ,  C07D207/12 ,  C07D207/14 ,  C07D207/16 ,  C07D207/34 ,  C07D209/94 ,  C07D211/60 ,  C07D211/76 ,  C07D213/74 ,  C07D213/81 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D231/56 ,  C07D233/61 ,  C07D239/42 ,  C07D249/04 ,  C07D257/04 ,  C07D261/18 ,  C07D261/20 ,  C07D277/56 ,  C07D295/088 ,  C07D295/12 ,  C07D295/15 ,  C07D295/26 ,  C07D311/08 ,  C07D333/34 ,  C07D333/38 ,  C07D413/12

Abstract: The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

公开(公告)号：US20240389583A1

公开(公告)日：2024-11-28

申请号：US18794040

申请日：2024-08-05

Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED

Inventor： Hiroto TAMASHIMA

IPC: A01N37/38 ,  A01N37/50 ,  A01N43/08 ,  A01N43/10 ,  A01N43/20 ,  A01N43/40 ,  A01N43/60 ,  A01N43/78 ,  A01N43/80 ,  A01N55/00 ,  C07C69/736 ,  C07C251/40 ,  C07D213/61 ,  C07D241/16 ,  C07D261/18 ,  C07D277/24 ,  C07D295/088 ,  C07D303/23 ,  C07D307/12 ,  C07D333/16 ,  C07F7/08

Abstract: The present invention provides a compound represented by formula (I) [wherein L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like, R1 represents a C1-C3 chain hydrocarbon group or the like, R2 represents a C1-C3 chain hydrocarbon group or the like, and n is 0, 1, 2 or 3.] or its N oxide or agriculturally acceptable salt, which is a compound that have excellent pests controlling effects.

公开(公告)号：US20240150376A1

公开(公告)日：2024-05-09

申请号：US18232435

申请日：2023-08-10

Applicant: Denali Therapeutics Inc.

Inventor： Anthony A. Estrada ,  Jianwen A. Feng ,  Brian Fox ,  Colin Phillip Leslie ,  Joseph P. Lyssikatos ,  Alfonso Pozzan ,  Zachary K. Sweeney ,  Javier de Vicente Fidalgo

IPC: C07D513/04 ,  C07D261/18 ,  C07D267/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14

CPC classification number: C07D513/04 ,  C07D261/18 ,  C07D267/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

公开(公告)号：US11739064B2

公开(公告)日：2023-08-29

申请号：US17099360

申请日：2020-11-16

Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Inventor： Alan Kozikowski ,  Irina Gaisina

IPC: A61K31/4155 ,  C07D261/10 ,  A61K45/06 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  A61K31/422 ,  C07D261/18 ,  A61K31/42 ,  A61K31/427 ,  A61P35/00

CPC classification number: C07D261/10 ,  A61K31/4155 ,  A61K31/42 ,  A61K31/422 ,  A61K31/427 ,  A61K45/06 ,  A61P35/00 ,  C07D261/18 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  Y02A50/30 ,  A61K31/422 ,  A61K2300/00 ,  A61K31/42 ,  A61K2300/00 ,  A61K31/4155 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00

Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.

公开(公告)号：US20230159474A1

公开(公告)日：2023-05-25

申请号：US17858840

申请日：2022-07-06

Applicant: Escient Pharmaceuticals, Inc.

Inventor： Adam Yeager ,  Brandon Selfridge ,  Marcos Sainz ,  Esther Martinborough ,  Marcus Boehm ,  Liming Huang

IPC: C07D265/30 ,  C07C69/78 ,  C07C255/41 ,  C07D213/79 ,  C07D241/24 ,  C07D261/18 ,  C07D277/64 ,  C07D333/38

CPC classification number: C07D265/30 ,  C07C69/78 ,  C07C255/41 ,  C07D213/79 ,  C07D241/24 ,  C07D261/18 ,  C07D277/64 ,  C07D333/38 ,  A61K45/06

Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):




or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

公开(公告)号：US11643399B2

公开(公告)日：2023-05-09

申请号：US17531660

申请日：2021-11-19

Applicant: Escient Pharmaceuticals, Inc.

Inventor： Adam Yeager ,  Brandon Selfridge ,  Marcos Sainz ,  Esther Martinborough ,  Marcus Boehm ,  Liming Huang

IPC: C07D265/30 ,  C07C69/78 ,  C07C255/41 ,  C07D213/79 ,  C07D241/24 ,  C07D261/18 ,  C07D277/64 ,  C07D333/38 ,  A61K45/06

CPC classification number: C07D265/30 ,  C07C69/78 ,  C07C255/41 ,  C07D213/79 ,  C07D241/24 ,  C07D261/18 ,  C07D277/64 ,  C07D333/38 ,  A61K45/06

Abstract: Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):




or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

公开(公告)号：US11634413B2

公开(公告)日：2023-04-25

申请号：US17445096

申请日：2021-08-16

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Melissa Fleury ,  Adam D. Hughes

IPC: C07D405/12 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  C07D231/14 ,  C07D231/20 ,  C07D249/04 ,  C07D261/18 ,  C07D263/38 ,  A61K45/06

Abstract: In one aspect, the invention relates to compounds having the formula: where X, Ra, Rb, R2, and R7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

公开(公告)号：US20220073452A1

公开(公告)日：2022-03-10

申请号：US17238529

申请日：2021-04-23

Applicant: Valo Early Discovery, Inc.

Inventor： Kenneth W. Bair ,  Nicholas Barczak ,  Bingsong Han ,  David R. Lancia, JR. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Xiaozhang Zheng

IPC: C07C259/06 ,  A61K31/185 ,  C07D221/20 ,  A61K31/438 ,  A61K31/277 ,  C07D209/44 ,  A61K31/4035 ,  C07D295/155 ,  A61K31/451 ,  C07D471/10 ,  A61K31/435 ,  C07D487/10 ,  A61K31/407 ,  C07D495/10 ,  A61K31/397 ,  C07D235/14 ,  A61K31/4184 ,  C07D233/68 ,  A61K31/417 ,  C07D213/56 ,  A61K31/44 ,  C07D241/08 ,  A61K31/495 ,  C07D417/04 ,  A61K31/4439 ,  A61K31/5377 ,  C07D471/04 ,  C07D401/14 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D317/68 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D241/12 ,  C07D417/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D487/04 ,  C07D487/08 ,  C07D491/10 ,  C07D207/10 ,  C07D493/08 ,  C07D207/267 ,  C07D498/04 ,  C07D209/08 ,  C07D277/56 ,  C07D209/42 ,  C07D209/46 ,  C07D513/10 ,  C07D211/16 ,  C07D211/58 ,  C07D295/192 ,  C07D213/65 ,  C07D307/68

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

公开(公告)号：US11130731B2

公开(公告)日：2021-09-28

申请号：US16535002

申请日：2019-08-07

Applicant: THE UNIVERSITY OF QUEENSLAND ,  THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

Inventor： Luke O'Neill ,  Rebecca Coll ,  Matthew Cooper ,  Avril Robertson ,  Kate Schroder

IPC: C07C311/56 ,  A61P5/00 ,  C07D403/12 ,  A61P37/00 ,  A61P35/00 ,  A61P3/00 ,  A61P25/00 ,  A61P1/00 ,  C07D215/36 ,  C07D401/12 ,  C07D487/04 ,  C07D493/04 ,  A61P17/00 ,  C07D213/71 ,  C07D309/08 ,  C07D311/18 ,  C07D311/60 ,  C07D217/22 ,  C07D217/24 ,  C07D495/04 ,  C07D217/02 ,  C07D221/18 ,  C07D241/42 ,  C07D307/68 ,  C07D311/16 ,  C07D333/52 ,  C07D307/82 ,  C07D307/64 ,  C07D307/18 ,  C07D277/36 ,  C07D498/04 ,  C07D207/38 ,  C07D495/06 ,  C07D271/12 ,  C07D261/18 ,  C07D249/12 ,  C07D249/06 ,  C07D249/04 ,  C07D417/12 ,  C07D241/44 ,  C07D317/62 ,  C07D231/18 ,  C07D333/34 ,  C07D333/62 ,  C07C311/60 ,  C07D405/12 ,  C07D407/12 ,  C07D413/12 ,  C07D241/24 ,  C07D235/02 ,  C07D401/06

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

公开(公告)号：US11098035B2

公开(公告)日：2021-08-24

申请号：US16510406

申请日：2019-07-12

Applicant: Proteostasis Therapeutics, Inc.

Inventor： Cecilia M. Bastos ,  Benito Munoz ,  Bradley Tait

IPC: C07D413/12 ,  A61K31/42 ,  A61K31/4245 ,  C07D413/14 ,  C07D409/14 ,  C07D417/12 ,  C07D261/18 ,  C07D307/54 ,  C07D405/12 ,  C07D407/12 ,  A61K31/422 ,  A61K31/433 ,  A61K31/5377 ,  A61K45/06 ,  C07D307/68 ,  G01N33/50

Abstract: The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.